Webometric analysis of the availability of semaglutide-based anti-obesity drugs
DOI:
https://doi.org/10.5281/zenodo.14274379Keywords:
obesity, overweight, semaglutide, COVID-19, illegal drug tradeAbstract
Introduction. According to the WHO, in 2022 every eighth person in the world suffers from obesity. Future forecasts are that by 2025, 167 million adults and children will experience poor health as a result of being overweight or obese. Accordingly, this issue gives rise to the need for people to find weight loss methods, and in recent years, drugs based on semaglutide have become in great demand as an easy way to lose weight, despite the presence of a large number of possible side effects. The purpose of this work was a webometric analysis of the availability of such drugs on the market of Ukraine. Materials and methods. The research materials were data from online search pages for medicines in pharmacies of Ukraine, as well as 12 websites that illegally offer to purchase the above-mentioned drugs were investigated. Webometrics, modeling and scientific generalization were used among the methods. Research results. After analyzing the pharmaceutical market of Ukraine, we found out that there is only one semaglutide-based drug registered in Ukraine – Ozempik. Currently, there is a shortage of this medicine, as there were only 27 offers for the availability of this drug in Ukrainian pharmacies as of 07/23/2024. Nevertheless, illegal Internet platforms (we have identified 10 online services that position themselves as platforms for the sale of drugs by delivery / imports them from European pharmacies, and 2 online services with biologically active supplements and sports nutrition) offer easy availability of Ozempik (injectable dosage form). In addition, there are two other medicines available for purchase on online resources - Vegovi (injectable dosage form) and Ribelsus (tablet dosage form), which are not registered in our country. Conclusion. The availability of semaglutide-based drugs in Ukraine was studied using a webometric search. Its shortage in licensed distribution points (pharmacies) was established, while the unimpeded presence of unlicensed sales was revealed, which requires strengthening of state control over the illegal trade in these medicines.
References
Public Health Center of the Ministry of Health of Ukraine. How to control your weight and calculate your body mass index, 2021. URL: https://www.phc.org.ua/news/yak-kontrolyuvati-svoyu-vagu-ta-rozrakhuvati-indeks-masi-tila (Date of access: 10.07.2023).
WHO. Obesity and overweight, 2024. URL: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight (Date of access: 10.07.2024).
Instruction 00499. Assessment of the obese patient, 2017. URL: https://guidelines.moz.gov.ua/documents/3335 (Date of access: 10.07.2024).
On the approval of the Instruction on the establishment of disability groups. Order of the Ministry of Health of Ukraine №561 from 05.09.2011. URL: https://zakon.rada.gov.ua/laws/show/z1295-11#Text (Date of access: 10.07.2024).
Tkach S., Pankiv V., Yuzvenko T. Modern approaches to the management of patients with obesity (according to the materials of the Consensus of the American Gastroenterological Association in 2022). Clinical endocrinology and endocrine surgery. №1, P.47-55. DOI: https://doi.org/10.30978/CEES-2023-1-47
Thelwall M. A history of webometrics. Bulletin of the American Society for Information Science and Technology. 2012. Vol. 36, №6, P.18-23. DOI: https://doi.org/10.1002/bult.2012.1720380606
Luk RWP. Understanding Scientific Study via Process Modeling. Foundations of Science. 2010, Vol. 15, P.49-78. DOI: https://doi.org/10.1007/s10699-009-9168-9
Payne G, Williams M. Generalization in Qualitative Research. Sociology 2005, Vol. 39, P.295-314. DOI: https://doi.org/10.1177/0038038505050540
WHO. World Obesity Day 2022 – Accelerating action to stop obesity, 2022. URL: https://www.who.int/news/item/04-03-2022-world-obesity-day-2022-accelerating-action-to-stop-obesity (Date of access: 10.07.2024).
WHO. New WHO/Europe report highlights a direct link between COVID-19 and increased obesity in school-aged children, 2024. URL: https://www.who.int/azerbaijan/news/item/01-05-2024-new-who-europe-report-highlights-a-direct-link-between-covid-19-and-increased-obesity-in-school-aged-children (Date of access: 10.07.2024).
WHO. The challenge of obesity, 2024. URL: https://www.who.int/europe/news-room/fact-sheets/item/the-challenge-of-obesity (Date of access: 10.07.2024).
PEOPLE. Stars Who've Spoken About Ozempic – and What They've Said, 2024. URL: https://people.com/celebrities-ozempic-wegovy-what-theyve-said-7104926 (Date of access: 12.07.2024).
Lexchin J, Mintzes B. Semaglutide: a new drug for the treatment of obesity. Drug Ther Bull. 2023. Vol. 61, №12, P. 182-188. DOI: https://doi.org/10.1136/dtb.2023.000007
RUGBANK Online. Semaglutide. URL: https://go.drugbank.com/drugs/DB13928 (Date of access: 18.07.2024).
State Register of Medicinal Products of Ukraine. Ozempik. URL: http://www.drlz.com.ua/ibp/ddsite.nsf/all/shlz1?opendocument&stype=7572F3BD42D18859C2258B2B002F1CD6 (Date of access: 18.07.2024).
For Health Care Professionals novoMEDLINK. Wegovy. URL: https://www.novomedlink.com/obesity/products/treatments/wegovy/resources/frequently-asked-questions.html (Date of access: 22.07.2024).
For Health Care Professionals novoMEDLINK. Rybelsus. URL: https://www.novomedlink.com/diabetes/products/treatments/rybelsus/dosing-administration/storage-and-administration.html (Date of access: 22.07.2024).
Klein H.E. An Ongoing Crisis: Semaglutide Shortage Raises Dual Concerns for Obesity and Diabetes Treatment. AJMS. 2023. URL: https://www.ajmc.com/view/an-ongoing-crisis-semaglutide-shortage-raises-dual-concerns-for-obesity-and-diabetes-treatment (Date of access: 22.07.2024).
Catanese L. GLP-1 diabetes and weight-loss drug side effects: "Ozempic face" and more. Harvard Health Publishing. Harvard Medical School. 2024. URL: https://www.health.harvard.edu/staying-healthy/glp-1-diabetes-and-weight-loss-drug-side-effects-ozempic-face-and-more (Date of access: 22.07.2024).
Hawkins-Jarrett Z.C. 19 Side Effects of Semaglutide for Type 2 Diabetes and Weight Loss. GoodRx Health. 2023. URL:https://www.goodrx.com/ozempic/semaglutide-side-effects (Date of access: 22.07.2024).
Shetty R, Basheer F.T, Poojari P.G, et al. Adverse drug reactions of GLP-1 agonists: A systematic review of case reports. Diabetes Metab Syndr. 2022. №3. DOI: https://doi.org/10.1016/j.dsx.2022.102427
Smits MM, Van Raalte DH. Safety of Semaglutide. Front Endocrinol (Lausanne). 2021. №12. DOI: https://doi.org/10.3389/fendo.2021.645563
Guirguis A, Chiappini S, Papanti P GD, et al. Exploring the association between suicidal thoughts, self-injury, and GLP-1 receptor agonists in weight loss treatments: Insights from pharmacovigilance measures and unmasking analysis. Eur Neuropsychopharmacol. 2024. Vol. 82, P.82-91. DOI: https://doi.org/10.1016/j.euroneuro.2024.02.003
Australian Government. Department of Health and Aged Care. About the Ozempic (semaglutide) shortage 2022 and 2024. 2024. URL: https://www.tga.gov.au/safety/shortages/information-about-major-medicine-shortages/about-ozempic-semaglutide-shortage-2022-and-2024 (Date of access: 23.07.2024).
Burger L., Mathews E. Novo rations Ozempic starter kits amid surge in use for weight loss. Reuters. 2023. URL: https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-says-diabetes-drugs-shortages-will-persist-through-2024-2023-11-21/ (Date of access: 23.07.2024).
WHO. Medical Product Alert №2/2024: Falsified OZEMPIC (semaglutide), 2024. URL: https://www.who.int/news/item/19-06-2024-medical-product-alert-n-2-2024--falsified-ozempic-(semaglutide) (Date of access: 23.07.2024).
FDA warns consumers not to use counterfeit Ozempic (semaglutide) found in U.S. drug supply chain, 2024. URL: https://www.fda.gov/drugs/drug-safety-and-availability/fda-warns-consumers-not-use-counterfeit-ozempic-semaglutide-found-us-drug-supply-chain (Date of access: 23.07.2024).
Tabletki.ua. URL: https://tabletki.ua./ (Date of access: 23.07.2024).
Sanafarma. URL: https://www.aptekasunfarma.com.ua/ua/ (Date of access: 23.07.2024).
farmdostavka. URL:https://farmdostavka.net/ (Date of access: 23.07.2024).
Apteka TLV. URL: https://apteka-tlv-ua.com/ (Date of access: 23.07.2024).
evromedics. URL: https://evromedics.com.ua/ (Date of access: 23.07.2024).
Yevroapteka. URL: https://euroapteka.in.ua (Date of access: 23.07.2024).
Internet pharmacy «Yevroapteka». URL: https://eapteka.org.ua/ (Date of access: 23.07.2024).
Farma Ekspres. URL: https://pharmaexpressz.com.ua/products/ (Date of access: 23.07.2024).
Aptekayevro. URL: https://aptekaevro.com.ua/ (Date of access: 23.07.2024).
Medlink. URL: https://medlink.in.ua/ (Date of access: 23.07.2024).
Apteka В12. URL: https://b12-apteka.com.ua/ (Date of access: 23.07.2024).
pharma247. URL: https://pharma247.com.ua/ (Date of access: 23.07.2024).
BCAA.PRO. URL: https://bcaa.pro/ (Date of access: 23.07.2024).
Tiva.Pharmaceuticals. URL: https://tiva-pharm.com.ua/ (Date of access: 23.07.2024).
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Annals of Mechnikov's Institute
This work is licensed under a Creative Commons Attribution 4.0 International License.
